EMD Serono

Showing 6 posts of 6 posts found.

FDA approves Pfizer and Merck KGaA’s Bavencio for maintenance of advanced bladder cancer

July 1, 2020
Research and Development, Sales and Marketing Bavencio FDA, EMD Serono, Merck, Pfier

The FDA has moved to approve Bavencio (avelumab), developed by Pfizer and EMD Serono, the biopharma arm of Merck KGaA, …


Bavencio Phase 3 head and neck cancer trial terminated

March 16, 2020
Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …


Ariad names EMD Serono’s Paris Panayiotopoulos as new president and chief exec

December 21, 2015
Sales and Marketing Ariad, Ariad Pharmaceuticals, EMD Serono, Paris Panayiotopoulos, harvey Berger

The board of directors at Ariad Pharmaceuticals has appointed Paris Panayiotopoulos as president and chief executive from 1 January 2016. …

Merck KGaA confirms leadership team appointments

June 20, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMD Serono, Merck KGaA, Serono

The subsidiary of Merck KGaA named EMD Serono has announced several appointments to its leadership team. The appointments include: Allene …

EMD Serono headquarters

FDA knocks back Merck KGaA’s oral MS drug

March 2, 2011
Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs

US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …

FDA approves Merck’s HIV fat drug Egrifta

November 12, 2010
Research and Development, Sales and Marketing EMD Serono, Egrifta, FDA, HIV, Merck KGaA, abdominal fat in HIV, tesamorelin

US regulatory authorities have approved the first treatment indicated to target abdominal fat in patients with HIV after trials showed …

Latest content